Industry in brief | Hypera, Reckitt Benckiser, FHCP

Industry in brief | Hypera, Reckitt Benckiser, FHCP

29 January 2021 - Deborah Wilkes

Hypera Pharma has completed the acquisition of a portfolio of OTC and pharmaceutical products from Takeda, Reckitt Benckiser (RB) has invested in the Bombay Shaving Company and a recent survey found the majority of Canadians support a national self-care strategy.

Hypera completes Takeda deal

Brazil’s Hypera Pharma has now completed the acquisition of a portfolio of OTC and pharmaceutical products in Latin America – including the Neosaldina brand – from Japan’s Takeda for USD825 million.

Following completion of the deal, Hypera went ahead with its planned divestment of 12 of the acquired products in Argentina, Colombia, Ecuador, Mexico, Panama and Peru to Eurofarma Laboratorios for USD161 million (click here to read the News story).

The company has also sold the Xantinon liver remedy to União Química Farmaceûtica Nacional.

Hypera announced in March 2020 that it was strengthening its presence in Latin America by acquiring a portfolio of OTC and pharmaceutical products from Takeda. The company said at the time that the deal was the biggest transaction in its history (click here to read the News story).

The deal came soon after Hypera announced the purchase of the Buscopan and Buscofem brands in Brazil (click here to read the News story).

Hypera said the Takeda transaction had “significantly” expanded its leadership in the Brazilian OTC market, and it now owned two of the three largest brands in the Brazilian OTC Market – Buscopan and Neosaldina.

RB invests in Bombay Shaving Company

Reckitt Benckiser (RB) has led a GBP4.0 million (USD5.5 million) funding round in Indian startup Bombay Shaving Company (BSC).

BSC has a portfolio of more than 100 products in the shaving, bath and body, skin, and beard care categories.

RB said the investment demonstrated its “commitment to innovative, purpose-driven brands” and was in line with its “strategy to play in new spaces and places”.

The UK-based company added that the investment would support BSC’s plans to “scale its operations” and provide it with “access to RB’s global scale, expertise and mentorship”.

Arjun Purkayastha – RB’s senior vice president, e-commerce, digital and ventures – will join the BSC board.

Purkayastha commented that the investment represented a “commitment to bring the best of two worlds together – BSC’s expertise in digital-first brands with strong e-commerce capabilities, and RB’s expertise in branding, manufacturing and global scale”.

BSC was launched in 2016 by ex-McKinsey & Co consultant Shantanu Deshpande.

The latest funding round is the fifth for BSC. Previous investors include Colgate-Palmolive.

Canadians support national self-care strategy

The vast majority of Canadians, 93%, support a national self-care strategy to help people take better care of themselves and make the healthcare system more sustainable in the face of rising costs, an ageing population and the COVID-19 crisis, according to a recent survey carried out on behalf of Food, Health & Consumer Products of Canada (FHCP).

Michael Graydon, the FHCP’s chief executive officer, commented: “To save time and money and keep our publicly-funded healthcare system sustainable, Canada must urgently develop a national strategy to improve health literacy and strengthen access to the self-care information, products, and services that will empower Canadians to take better care of themselves.”

The survey was carried out by Abacus Data.

Click tags below for more information on topics:

Hypera Pharma RB

Back to Industry News

Share this page: